ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Sold by Victory Capital Management Inc.

Victory Capital Management Inc. decreased its holdings in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) by 2.3% during the 4th quarter, HoldingsChannel.com reports. The firm owned 97,500 shares of the company’s stock after selling 2,250 shares during the period. Victory Capital Management Inc.’s holdings in ORIC Pharmaceuticals were worth $787,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ORIC. Charles Schwab Investment Management Inc. increased its position in ORIC Pharmaceuticals by 152.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 410,229 shares of the company’s stock worth $4,205,000 after purchasing an additional 247,863 shares during the period. Franklin Resources Inc. increased its position in ORIC Pharmaceuticals by 26.1% during the 3rd quarter. Franklin Resources Inc. now owns 950,459 shares of the company’s stock worth $9,067,000 after purchasing an additional 196,804 shares during the period. Sphera Funds Management LTD. acquired a new position in ORIC Pharmaceuticals during the 3rd quarter worth approximately $1,316,000. Alkeon Capital Management LLC increased its position in ORIC Pharmaceuticals by 2.6% during the 3rd quarter. Alkeon Capital Management LLC now owns 3,904,096 shares of the company’s stock worth $40,017,000 after purchasing an additional 100,000 shares during the period. Finally, ArrowMark Colorado Holdings LLC increased its position in ORIC Pharmaceuticals by 6.4% during the 3rd quarter. ArrowMark Colorado Holdings LLC now owns 1,354,508 shares of the company’s stock worth $13,884,000 after purchasing an additional 80,986 shares during the period. Institutional investors and hedge funds own 95.05% of the company’s stock.

Wall Street Analyst Weigh In

ORIC has been the topic of a number of research reports. Cantor Fitzgerald restated an “overweight” rating on shares of ORIC Pharmaceuticals in a report on Tuesday, January 14th. Wedbush restated an “outperform” rating and issued a $20.00 price target on shares of ORIC Pharmaceuticals in a report on Thursday. JPMorgan Chase & Co. upped their price target on ORIC Pharmaceuticals from $21.00 to $22.00 and gave the stock an “overweight” rating in a report on Wednesday, February 26th. HC Wainwright restated a “buy” rating and issued a $21.00 price target on shares of ORIC Pharmaceuticals in a report on Friday, February 21st. Finally, Guggenheim restated a “buy” rating on shares of ORIC Pharmaceuticals in a report on Wednesday, February 26th. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $18.86.

ORIC Pharmaceuticals Stock Performance

ORIC stock opened at $7.51 on Friday. ORIC Pharmaceuticals, Inc. has a 1 year low of $6.33 and a 1 year high of $15.35. The stock’s 50 day moving average price is $9.09 and its 200 day moving average price is $9.26. The firm has a market cap of $533.41 million, a P/E ratio of -4.13 and a beta of 1.25.

ORIC Pharmaceuticals (NASDAQ:ORIC) last posted its earnings results on Tuesday, February 18th. The company reported ($0.51) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.01. On average, research analysts predict that ORIC Pharmaceuticals, Inc. will post -2.17 earnings per share for the current year.

About ORIC Pharmaceuticals

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.